Bernd Schneider to join N+1 Group

Bernd Schneider (43) has joined N+1 Group as Global Head of Chemicals
Bernd Schneider (43) has joined N+1 Group as Global Head of Chemicals

Bernd Schneider (43) has joined N+1 Group, a leading pan-European investment bank for small and mid-cap transactions, as Global Head of Chemicals effective on 1 November. He will operate as Partner and Managing Director out of the Group's Frankfurt office. Wolfram Schmerl, N+1 Germany's CEO says: "Bernd Schneider will further strengthen and expand the activities of N+1 Group in the chemicals and related industries where he will leverage his large international industry network and his long-standing deal experience. This addition will improve N+1 Group's overall market position in chemicals on a global scale."

Dr Schneider studied chemistry and business administration at the University of Bayreuth (Germany) and earned a PhD degree in polymer chemistry at Bayreuth University and UCSB Santa Barbara. Mr. Schneider advised on more than 40 transactions covering all relevant segments of the chemicals and related industries. He is focussed on transactions with large and mid-sized chemicals companies and financial sponsors with interest in chemicals and related industries. Prior to joining N+1 Mr. Schneider was Head of Chemicals at Lincoln International for more than 3 years and systematically developed and expanded the Group's sector coverage. In previous stages of his career he held leading positions in the "Chemicals Competence Center" of PwC's transaction services division and in the DENOx catalysts division of Siemens.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.